DioSynVax 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, DIOS-CoVax2 / University of Cambridge, DioSynVax, University Hospitals Southampton NHS Trust
    The receptor binding domain as a target for variant proof and pansarbecovirus vaccines (THE STUDIO) -  Sep 13, 2022 - Abstract #OPTIONSXI2022OPTIONS_XI_104;    
    Conclusion The RBD is a viable target for booster vaccination against SARS-CoV-2, and as part of wider efforts to vaccinate against a variety of circulating or zoonotic potential viruses. Hybrid structurally modified RBDs containing crossreactive neutralising or binding antibody epitopes are an important component of optimised antigens in the development of a pan-coronavirus vaccine.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, DIOS-CoVax2 / University of Cambridge, DioSynVax, University Hospitals Southampton NHS Trust
    Journal:  Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. (Pubmed Central) -  Apr 15, 2022   
    Infection-acquired immunity boosted with vaccination remained high more than 1 year after infection. (Funded by the U.K. Health Security Agency and others; ISRCTN Registry number, ISRCTN11041050.).
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Clinical, Journal:  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. (Pubmed Central) -  Sep 10, 2021   
    Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.